老年肺炎球菌多糖疫苗免疫反应和保护效果研究进展  

Immune and protective effect of pneumococcal polysaccharide vaccine in elderly population: a review

作　　者：许玉洋[1] 刘艳[1] 安志杰[2] XU Yu-yang;LIU Yan;AN Zhi-jie(Department of Expanded Program on Immunization,Hangzhou Municipal Center for Disease Control and Prevention,Hangzhou,Zhejiang Province 310021,China;不详)

机构地区：[1]杭州市疾病预防控制中心免疫预防所,浙江310021 [2]中国疾病预防控制中心

出　　处：《中国公共卫生》2021年第4期584-588,共5页Chinese Journal of Public Health

基　　金：杭州市科技计划引导项目(农业和社会发展)(20191231Y053)。

摘　　要：肺炎链球菌是引起婴幼儿和老年人发病和死亡的重要病因,肺炎球菌性疾病是全球较为严重的公共卫生问题之一,肺炎球菌疫苗是预防肺炎链球菌感染的有效手段,23价肺炎球菌多糖疫苗(PPSV23)是目前成人高危人群最常用的预防肺炎球菌性疾病(PD)的疫苗,尤其对于老年人群。国内外研究均显示PPSV23具有较好的安全性和保护效果,老年人群接种PPSV23,可减少其侵袭性肺炎球菌性疾病(IPD)及呼吸道感染性疾病的发病,减轻PD疾病负担,既能提升老年人群的健康,又可节省大量医疗资源,因此PPSV23值得在老年人群中推广应用。Streptococcus pneumoniae is an important pathogen causing morbidity and mortality of in infants and the elderly and pneumococcal disease(PD) is one of the serious public health problems worldwide. Vaccine is an effective measure for pneumococcal infection prevention. Nowadays, 23-valent pneumococcal polysaccharide vaccine(PPSV23) is the most commonly used vaccine among adult high risk population, especially among the elderly, for PD prevention. Studies at home and abroad indicated that PPSV23 was safe and effective. PPSV23 vaccination can reduce the incidence of invasive pneumococcal disease(IPD) and respiratory infectious diseases, decrease PD disease burden, and improve health in elderly populations.

关 键 词：老年人 肺炎球菌多糖疫苗 免疫效果 保护效果 

分 类 号：R186[医药卫生—流行病学]